BSCCG
MRNA icon

Blue Sky Capital Consultants Group’s Moderna MRNA Stock Holding History

Blue Sky Capital Consultants Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Buy
21,943
+1,355
+7% +$70.1K 0.66% 30
2026
Q1 		$1.05M Buy
20,588
+143
+0.7% +$6.67K 0.5% 38
2025
Q4 		$603K Buy
20,445
+1,359
+7% +$36.9K 0.26% 44
2025
Q3 		$493K Buy
19,086
+2,732
+17% +$76.2K 0.21% 46
2025
Q2 		$451K Buy
16,354
+1,235
+8% +$32.5K 0.23% 43
2025
Q1 		$429K Buy
15,119
+556
+4% +$19.7K 0.28% 41
2024
Q4 		$606K Buy
+14,563
New +$696K 0.36% 38

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Blue Sky Capital Consultants Group's MRNA Position: Q2 2026 in Review

Blue Sky Capital Consultants Group increased its Moderna (MRNA) stake by 6.6% in Q2 2026, buying an estimated $70.1K and bringing the position to 21,943 shares worth $1.54M. The position accounts for 0.66% of the portfolio, ranked #30.

Blue Sky Capital Consultants Group first reported a position in MRNA in Q4 2024 and has held it in 7 quarters since. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Blue Sky Capital Consultants Group held 21,943 shares of Moderna worth $1.54M as of Q2 2026.
  • Blue Sky Capital Consultants Group bought 1,355 Moderna shares in Q2 2026, an estimated $70.1K.
  • Moderna made up 0.66% of Blue Sky Capital Consultants Group's portfolio in Q2 2026, its #30 holding.
  • Blue Sky Capital Consultants Group first reported a position in Moderna in Q4 2024 and has held it in 7 quarters since.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Blue Sky Capital Consultants Group's 13F filing for Q2 2026, filed 4 Aug 2026.